About: Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://dx.doi.org/10.2174/1871529X11313010003
Description	Multiple myeloma (MM) remains an incurable disease, at least for the big majority of patients, in spite of the great progress with new drugs in the last years. New treatment strategies are needed to improve the outcome of patients. At least, five proteasome inhibitors of the next generation with greater efficacy (carfilzomib, marizomib (salinosporamide A, NPI-0052), threonine boronic acid-derived proteasome inhibitor CEP-18770, the peptide-semicarbazone S-2209, the tripeptide mimetic BSc2118, and MLN9708/2238) have been recently tested in preclinical models of MM. Carfilzomib has been recently approved for the treatment of patients with MM who have received at least two prior therapies, including bortezomib and immunomodulatory derivatives (IMiDs, thalidomide, lenalidomide or pomalidomide). Multiple myeloma (MM) remains an incurable disease, at least for the big majority of patients, in spite of the great progress with new drugs in the last years. New treatment strategies are needed to improve the outcome of patients. At least, five proteasome inhibitors of the next generation with greater efficacy (carfilzomib, marizomib (salinosporamide A, NPI-0052), threonine boronic acid-derived proteasome inhibitor CEP-18770, the peptide-semicarbazone S-2209, the tripeptide mimetic BSc2118, and MLN9708/2238) have been recently tested in preclinical models of MM. Carfilzomib has been recently approved for the treatment of patients with MM who have received at least two prior therapies, including bortezomib and immunomodulatory derivatives (IMiDs, thalidomide, lenalidomide or pomalidomide). (en)
Title	Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma (en)
skos:prefLabel	Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma (en)
skos:notation	RIV/00023736:_____/13:00010697!RIV14-MZ0-00023736
http://linked.open...avai/riv/aktivita	I P
http://linked.open...avai/riv/aktivity	I, P(NT13836)
http://linked.open...iv/cisloPeriodika	1
http://linked.open...vai/riv/dodaniDat	2014
http://linked.open...aciTvurceVysledku	Fuchs, Ota
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Ústav hematologie a krevní transfúze
http://linked.open...dnocenehoVysledku	109833
http://linked.open...ai/riv/idVysledku	RIV/00023736:_____/13:00010697
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	apoptosis; IkBalpha; MEK/MAPK; multiple myeloma; NF-kappaB; PI3K/akt/mTOR (en)
http://linked.open.../riv/klicoveSlovo	IkBalpha MEK/MAPK PI3K/akt/mTOR multiple myeloma apoptosis NF-kappaB
http://linked.open...odStatuVydavatele	NL - Nizozemsko
http://linked.open...ontrolniKodProRIV	[E18DDE71BE8F]
http://linked.open...i/riv/nazevZdroje	Cardiovascular & hematological disorders drug targets
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	1 (xsd:int)
http://linked.open...vavai/riv/projekt	The study of the myelodysplastic syndrome pathogenesis in patients with isolated del(5q) abnormality and the analysis of the effect of lenalidomide
http://linked.open...UplatneniVysledku	2013
http://linked.open...v/svazekPeriodika	13
http://linked.open...iv/tvurceVysledku	Fuchs, Ota
issn	1871-529X
number of pages	18 (xsd:int)
http://bibframe.org/vocab/doi	10.2174/1871529X11313010003

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 77 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software